MSD spent $6.7 billion to buy Terns Pharmaceuticals to bolster its pipeline of cancer drugs. [user query] Lead candidate Terns has shown "unprecedented data" in chronic myeloid leukemia, according to analysts. [user query] However, none of the sources provided mention the purchase of Terns Pharmaceuticals or this specific candidate data.[1][2][3][4][5] MSD has recently announced other acquisitions, such as the $10 billion purchase of Verona Pharma to expand its portfolio outside of oncology.[2][5] It is also considering a $28-32 billion takeover of Revolution Medicines for a pancreatic cancer candidate in early clinical trials.[1] The moves are related to expansion after Keytruda's patent expires in 2028.[2][3]